Objective: To develop in-situ gel formulations of Lornoxicam for sustained release to reduce the dosing frequency in treatment rheumatoid arthritis. Methods: The method ion-sensitive formation was used this study. situ were prepared by varying concentrations sodium alginate as a bio-degradable gel-forming polymer, CaCl2 cross-linking agent, and chitosan, HPMCK4, HPMCK15, guar gum, gellan xantha...

Niosomes are non-ionic surfactant vesicles obtained on hydration of synthetic nonionic surfactants, with or without incorporation of cholesterol or other lipids. They are vesicular systems similar to liposomes that can be used as carriers of amphiphilic and lipophilic drugs. Niosomes are promising vehicle for drug delivery and being non-ionic, it is less toxic and improves the therapeutic index...

The present paper describes simple and sensitive, reversed phase high performance liquid chromatography (RP-HPLC) method has been developed for the determination of lornoxicam in bulk and its tablet dosage form. Chromatographic separation was achieved by using phenomenex C18 column, 250×4.6 mm, 5 μm as stationary phase. Mixture of acetonitrile: phosphate buffer (60:40 v/v) was used as a mobile ...

Pain relieving drugs are one of the most commonly used drugs worldwide either through prescription or as over the counter medication. Non-steroidal anti-inflammatory drugs usually abbreviated as NSAIDs, are the drugs with analgesic, antipyretic and, in higher doses, with antiinflammatory effects. NSAIDs inhibit cyclooxygenase (COX) 1 and 2. So, most of the side effects develop as a result of cy...

A single oral dose of chlortenoxicam 4 mg, a new non-steroidal anti-inflammatory drug, significantly antagonized the diuretic and natriuretic actions of frusemide when compared with placebo in normal human volunteers. Indomethacin 50 mg significantly reduced the natriuretic, but not diuretic action of frusemide.

Forty-five healthy men aged 21-34 years took part in a double-blind, parallel-group, placebo-controlled study of the effects of 28 days' treatment with lornoxicam 4 mg twice daily or indomethacin 50 mg twice daily on faecal blood loss and the endoscopic appearances of gastric and duodenal mucosa. After an initial endoscopic examination, subjects received, intravenously, on day 0, autologous ery...

The objective of the existing research was formulation development and preparation microemulsion loaded emulgel in augmenting topical delivery Lornoxicam. Emulsion gel combined are recognized as Emulgels. Gelling agents Carbopol 940, 974, 980 were used to formulating Lornoxicam emulgel. drug release from determined depending on different gelling agents. Clove oil for internal phase Polyethylene...

In the current research, diffusion controlled transdermal matrix patches of Lornoxicam, an anti-inflammatory drug was developed by solvent casting method using hydrophilic and hydrophobic polymers in different ratios tween-80 span-80 as permeation enhancers. Formulated were characterized for physicochemical parameters terms moisture loss, content, film thickness strength, uptake loss moisture, ...